Mitomycin (Gastric Cancer) - Analysis and Forecasts to 2020


#28402

29pages

GlobalData

$ 2000

In Stock


GlobalDatas pharmaceuticals report, Mitomycin (Gastric Cancer) - Analysis and Forecasts to 2020 provides Mitomycin sales estimates for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2002-2020). The report also includes information on Oncology's Disease market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

Scope

  • Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
  • Analysis and review of Mitomycin including historical sales data
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of Mitomycin including efficacy, safety, pricing, competition and other details which influence its sales potential
  • Detailed sales forecast for 2002-2020 for Mitomycin in each of the US, EU and Japan markets

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drugs performance 
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets
Table of Contents

1 Table of contents 2
1.1 List of Tables 2
1.2 List of Figures 2

2 Introduction 4
2.1 Gastric Cancer Market 4
2.2 Gastric Cancer Disease 4
2.3 GlobalData Pipeline Report Guidance 6

3 Gastric Cancer Disease: Market Characteristics 7
3.1 Gastric Cancer Disease Market 7
3.2 Gastric Cancer Disease Market Forecasts 7
3.3 Drivers for the Gastric Cancer Disease Market 7
3.3.1 High Prevalence 8
3.3.2 High Incidence 8
3.3.3 High Survival Rate 9
3.3.4 High Mortality Rate 9

4 Tumor Node Metastases (TNM) Classification of gastric cancer 10

5 Mitomycin 13

5.1 Introduction 13
5.2 Mechanism of Action 13
5.3 Clinical Studies 13
5.4 Approval History of Mitomycin 15
5.5 Factors Affecting Sales of Mitomycin 15
5.5.1 Gastric Cancer Market 15
5.5.2 Importance of Neo-Adjuvant Chemotherapy 15
5.5.3 Better Safety Profile 16
5.5.4 High Response Rate 16
5.5.5 Emergence of New Drugs 16
5.6 Drug Risk Benefit Score (DRB) 16
5.6.1 Efficacy 17
5.6.2 Safety 17
5.6.3 Compliance 17
5.6.4 Dosing Convenience 17
5.7 Intensity of Competition 17
5.8 Sales forecast 17
5.8.1 Target patient Pool of Mitomycin 17
5.8.2 Dosing 19
5.8.3 Market Penetration 20
5.8.4 Annual Cost of Therapy 20
5.8.5 Sales Projections of Mitomycin 20

6 Gastric Cancer Market: Appendix 27
6.1 Market Definitions 27
6.2 List of Abberiviations 27
6.3 Research Methodology 27
6.3.1 Coverage 27
6.3.2 Secondary Research 27
6.3.3 Forecasting 28
6.3.4 Number of Patients Approved to take the Drug 28
6.3.5 Net Penetration of Drug 28
6.3.6 Net Annual Dosing 28
6.3.7 Annual Cost of Therapy 29
6.3.8 Primary Research 29
6.3.9 Expert Panels 29
6.4 Contact Us 29
6.5 Disclaimer 29
6.6 Sources 29

Table 1: Gastric Cancer Incidences and Mortality, 2008-2030 5
Table 2: Gastric Cancer, Global, Market Forecast ($bn), 20022020 7
Table 3: Approval History of Mitomycin 15
Table 4: Drug Risk Benefit Score 16
Table 5: Gastric Cancer, The US, EU-5 and Japan, Sales Forecast for Mitomycin ($m), 20022020 21
Table 6: Gastric Cancer, The US, Sales Forecast for Mitomycin ($m), 20022020 22
Table 7: Gastric Cancer, The UK, Sales Forecast for Mitomycin ($m), 20022020 23
Table 8: Gastric Cancer, France, Sales Forecast for Mitomycin ($m), 20022020 24
Table 9: Gastric Cancer, Germany, Sales Forecast for Mitomycin ($m), 20022020 25
Table 10: Gastric Cancer, Italy, Sales Forecast for Mitomycin ($m), 20022020 26
Table 11: Gastric Cancer, Spain, Sales Forecast for Mitomycin ($m), 20022020 27
Table 12: Gastric Cancer, Japan, Sales Forecast for Mitomycin ($m), 20022020 28
Figure 1: Percentage Distribution of Top 20 Cancers 4
Figure 2: Fatality = [(%Distribution of Incidence) (% Distribution Mortality )] of Top 20 Cancers 5
Figure 3: Per Capita Cigarette Consumption , The US, 1976-2006 6
Figure 4: Gastric Cancer , Global Market Size Forecasts ($bn), 2009-2020 7
Figure 5: Oncology, Global, Estimated Incidence 2008-2030 8
Figure 6: Gastric Cancer, Global, Estimated Incidence 2008-2030 8
Figure 7: Broad Classification of Gastric Cancer in the US and EU-5 10
Figure 8: Broad Classification of Gastric Cancer in Japan 10
Figure 9: Detailed TNM Classifications 11
Figure 10: Classification of Gastric Cancer (US and EU) 12
Figure 11: Classification of Gastric Cancer (Japan) 12
Figure 12: Drug Model Diagram of Mitomycin for the US and EU 18
Figure 13: Drug Model Diagram of Mitomycin for Japan 19
Figure 14: Drug Dosage Diagram of Mitomycin for the US and EU 19
Figure 15: Gastric Cancer, The US, EU-5 and Japan, Sales Forecast for Mitomycin ($m), 20022020 20
Figure 16: Distribution of Mitomycin sales in the US, EU-5 and Japan (2010) 21
Figure 17: Gastric Cancer, The US, Sales Forecast for Mitomycin ($m), 20022020 22
Figure 18: Gastric Cancer, The UK, Sales Forecast for Mitomycin ($m), 20022020 23
Figure 19: Gastric Cancer, France, Sales Forecast for Mitomycin ($m), 20022020 24
Figure 20: Gastric Cancer, Germany, Sales Forecast for Mitomycin ($m), 20022020 25
Figure 21: Gastric Cancer, Italy, Sales Forecast for Mitomycin ($m), 20022020 26
Figure 22: Gastric Cancer, Spain, Sales Forecast for Mitomycin ($m), 20022020 27
Figure 23: Gastric Cancer, Japan, Sales Forecast for Mitomycin ($m), 20022020 28